Literature DB >> 26110681

Aspirin desensitization for cardiovascular disease.

Katharine M Woessner1.   

Abstract

PURPOSE OF REVIEW: The use of aspirin in coronary artery disease and address the unmet need of aspirin therapy in patients with history of hypersensitivity reactions to aspirin (acetylsalicylic acid; ASA) or other nonsteroidal inflammatory drugs (NSAIDs). RECENT
FINDINGS: Aspirin hypersensitivity is reported in 1.5% of patients with cardiovascular disease. However, many of those labeled as allergic to aspirin had experienced side-effects and could be safely treated with aspirin. Those with true hypersensitivity reactions were often not placed on appropriate antiplatelet therapy. A number of protocols of varying complexity exist in the literature for aspirin desensitization. The focus of this review is to identify the types of aspirin reactions that can occur and provide a rational approach to oral aspirin challenge and desensitization.
SUMMARY: In summary, with rare exceptions, patients with a history of 'aspirin/NSAID allergy' who need ASA for cardiovascular issues will be able to safely take aspirin either after a graded challenge or desensitization providing a central role of the allergist in the management of these patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26110681     DOI: 10.1097/ACI.0000000000000189

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  5 in total

1.  Aspirin allergy labeling after desensitization: education, communication, and patient safety.

Authors:  Jyotsna Mullur; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol Pract       Date:  2020-06-22

Review 2.  Rapid Aspirin Challenge in Patients with Aspirin Allergy and Acute Coronary Syndromes.

Authors:  Kevin A Cook; Andrew A White
Journal:  Curr Allergy Asthma Rep       Date:  2016-02       Impact factor: 4.806

Review 3.  Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.

Authors:  Whitney Stevens; Kathleen Buchheit; Katherine N Cahill
Journal:  Curr Allergy Asthma Rep       Date:  2015-12       Impact factor: 4.806

Review 4.  Practical Management of Patients with a History of Immediate Hypersensitivity to Common non-Beta-Lactam Drugs.

Authors:  Eric Macy
Journal:  Curr Allergy Asthma Rep       Date:  2016-01       Impact factor: 4.806

Review 5.  Desensitization for the prevention of drug hypersensitivity reactions.

Authors:  Sung-Yoon Kang; Jeongmin Seo; Hye-Ryun Kang
Journal:  Korean J Intern Med       Date:  2022-02-28       Impact factor: 2.884

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.